Abstract: Medical and other research organizations, sites within those organizations, and physicians practicing at those sites register in an online database. The company providing the database posts a description of a clinical trial opportunity or other research opportunity. The company can search and match for physicians with research opportunities, or the physicians can browse the list of opportunities. Once it is determined who will perform the research and awarded a contract, performance data are collected at 30-day intervals over the life of the trial for computation of benchmarks. The benchmarks from one physician are compared anonymously to those from other physicians participating in the same opportunity.

Abstract: Medical and other research organizations, sites within those organizations, and physicians practicing at those sites register in an online database. The company providing the database posts a description of a clinical trial opportunity or other research opportunity. The company can search and match for physicians with research opportunities, or the physicians can browse the list of opportunities. Once it is determined who will perform the research and awarded a contract, performance data are collected at 30-day intervals over the life of the trial for computation of benchmarks. The benchmarks from one physician are compared anonymously to those from other physicians participating in the same opportunity.

Abstract: Medical and other research organizations, sites within those organizations, and physicians practicing at those sites register in an online database. The company providing the database posts a description of a clinical trial opportunity or other research opportunity. The company can search and match for physicians with research opportunities, or the physicians can browse the list of opportunities. Once it is determined who will perform the research and awarded a contract, performance data are collected at 30-day intervals over the life of the trial for computation of benchmarks. The benchmarks from one physician are compared anonymously to those from other physicians participating in the same opportunity.

Abstract: The invention provides high purity branched alkylsilsesquioxane containing fluids of the general formula Me.sub.3 SiO--(Me.sub.3 SiORSiO).sub.x --SiMe.sub.3, wherein Me is methyl, R is a monovalent hydrocarbon substituent, and x is 1 to 6, and an essentially zero waste process for their synthesis in quantitative yield; and especially n-octylsilsesquioxane containing fluids which are structural analogs of phenylsilsesquioxane containing fluids of the general formula Me.sub.3 SiO--(Me.sub.3 SiOPhSiO).sub.x --SiMe.sub.3, wherein Me is methyl, Ph is phenyl, x is 1 to 6, and have substantially identical sensory properties to their phenylsilsesquioxane counterparts.

Abstract: Compositions of unstrained perfluorinated organo substituted cyclosiloxanes of formula (I): ##STR1## wherein m is an integer of 1 to 12; n is an integer of 1 to 4; X is a divalent radical which may include O, NH, N(CH.sub.3), OC(O), NHC(O), N(CH.sub.3)C(O)CH.sub.2 ; and R.sup.F is a perfluorinated straight chain or branched chain monovalent alkyl radical of 1 to 25 carbon atoms; or R.sup.F is a perfluorinated ether radical of the general formula (II): ##STR2## wherein p is an integer of 1 to 10 are described, along with copolymer compositions prepared from these cyclopolysiloxanes and from mixtures of these cyclosiloxanes and other siloxanes.

Abstract: The invention provides high purity 3-aminopropylmethylsiloxanes of the general formulae: ##STR1## wherein each R may be the same or different aryl group, or monovalent straight or branched chain alkyl group having from 1 to about 18 carbon atoms, Me is methyl, and x may range from about 3 to about 5, the process comprisinghydrosilylating allylamine with a monohydridomethylsiloxane of the general formulae: ##STR2## wherein each R may be the same or different aryl group, or monovalent straight or branched chain alkyl group with 1 to about 18 carbon atoms, and x may range from about 3 to about 5, in the presence of a neutral platinum catalyst.

Abstract: Compositions of unstrained perfluorinated ether organo substituted cyclosiloxanes of formula (I): ##STR1## wherein m is an integer of 1 to 12; n is an integer of 1 to 4; X is a divalent radical which may include O, NH, N(CH.sub.3), OC(O), NHC(O), N(CH.sub.3)C(O)CH.sub.2 ; and R.sup.F is a perfluorinated ether radical of the general formula (II): ##STR2## wherein p is an integer of 1 to 10 are described, along with copolymer compositions prepared from these cyclopolysiloxanes and from mixtures of these cyclosiloxanes and other siloxanes.

Abstract: The invention provides high purity alkoxytrimethylsilane fluids of the general formula ROSiMe.sub.3 wherein Me is methyl and R is a monovalent aliphatic hydrocarbon substituent which ranges from 14 to about 20 carbons, the fluid being substantially free of organic and inorganic contaminants, wherein the alkoxytrimethylsilanes are produced by a novel process, and can be readily incorporated into cosmetic formulations containing organic components without heating and provide improved sensory characteristics compared to those provided by the corresponding alcohols.

Abstract: The invention provides high purity branched phenylsilsesquioxane containing fluids of the general formula Me.sub.3 SiO--(Me.sub.3 SiOPhSiO).sub.x --SiMe.sub.3, wherein Me is methyl, Ph is phenyl, and x is 1 to 6, and an essentially zero waste process for their synthesis in quantitative yield.

Abstract: The invention is directed to the preparation of fluorosilanes, such as, for example, alkyl, cycloalkyl, aryl, alkoxy, aryloxy and siloxy fluorosilanes by the action of hydrogen fluoride on substrates containing at least one silicon-hydride bond.

Abstract: A process is provided for the preparation of certain 2-deoxyuridines including the steps forming a substituted alkyl 5-O-"protected"-2-deoxyribofuranoside, hydrocarbylating the latter compound, and condensing the hydrocarbylated compound in the presence of a Lewis or Bronsted acid with a silyluracil to form a uridine. Several tritylated ribofuranosides are novel compounds per se.

Abstract: Expanded perlite compositions containing thereon, therein or thereon and therein buffered aqueous silane emulsion compositions as well as hydrophobic expanded perlite compositions as described above but from which residual water has been removed are provided. A process for the preparation of the same is also provided.

Abstract: There are provided aqueous emulsions useful for rendering porous substrates water repellent comprising (a) a hydrolyzable silane having a determinable pH-stable range, (b) an emulsifying agent having an HLB value of from 2 to 20, an effective amount of (c) a buffering compound to maintain the composition within the pH-stable range; and (d) water. Such buffered compositions are stable on long term storage and maintain high effective levels of active silane content even when they include biocides which may accelerate the hydrolysis of aqueous silane-containing compositions.

Abstract: There is provided an improved solvent especially adapted for cleaning silicon wafers and consisting essentially of a haloalkylhydrocarbon and a partially fluorinated alcohol. This solvent provides excellent cleaning and drying of the wafer.

Abstract: There is provided a method and compositions for improving the resistance to absorption of water by a porous rigid sintered and pressed block of short staple amorphous silica fiber by distributing within the pores of said block an alkylalkoxysilane or a fluoroalkylalkoxysilane which is substantially free of deleterious halide. Halide may be reduced by special purification techniques or by netralization in situ with acid scavanger.

Abstract: There is provided a novel product having the formula: ##STR1## where "polymer" is an amine functional polymer, such as amine terminated polyethylene imine, amine terminated polyalkylene glycols, amine terminated anilineformaldehyde, amine terminated nylons, amine functional silicones; R.sup.1, R.sup.2, and R.sup.3 are C.sub.1 -C.sub.8 monovalent hydrocarbyl radicals, m is 1 to 3 and n is 1 to 10.

Abstract: The invention relates to a novel fluorinated pre-polymer and novel process steps in producing the same. The pre-polymers are quinoxaline materials derived by reaction of diketone linkage containing perfluoro-compounds with an aromatic diamine. The diketone is produced by a bis-ketone. The polychloroketone is produced by reacting a keto-ylid with a chlorinating agent, e.g., chlorine. The keto-ylid is produced by oxidatively dechlorinating a polychloroketone which may be a monoketone or reacting a phosphorane with an acid halide of a polyoxy-perfluoroalkylene oxide wherein the perfluoro-oxyalkylene group contains two or three carbon atoms, and there are present from two or twenty perfluoro-oxyalkylene units in the oligomer. The quinoxalines, the polychloroketones and the diketones hereof are novel products. Cross-linking may be effected with a free radical generator.

Abstract: There is provided an improved silica filler for resins which silica filler is coated or reacted with an alkoxyepoxyterpene silane. The resins containing such filler are characterized by improved dielectric constant and dissipation factor.

Abstract: Pharmaceutical compositions suitable for the treatment of Herpes or Herpes-like viruses are disclosed, wherein the compositions contain 5-trifluoromethyl-2'-deoxycytidine and a cytidine deaminase inhibitor. Also disclosed are methods of treating patients suffering from a disease caused by a Herpes or Herpes-like virus, with the method comprising administering to the patient a therapeutically effective amount of 5-trifluoromethyl-2'-deoxycytidine and a cytidine deaminase inhibitor.

Abstract: Direct fluorination of uracil and its derivatives, in the presence of an aqueous solvent, by fluorine gas to produce 5-fluorouracil and 5-fluorouracil derivatives is disclosed. Novel compounds produced by the reaction, such as 5,5-difluoro-6-hydroxy-5,6-dihydrouracil are also disclosed. The derivatives of 5-fluorouracil are useful as germicidal agents while 5-fluorouracil itself is a known cancer chemotherapy agent.